PLYMOUTH MEETING, PA — New research published in the July 2025 issue of JNCCN—Journal of the National Comprehensive Cancer Network offers encouraging news for men diagnosed with nonmetastatic prostate ...

Up to 5,000 men a year could avoid potentially harmful treatment for prostate cancer if ‘outdated’ guidelines reflected the latest evidence, a charity has said. Closely monitoring the disease with ...

Patients who receive guideline-concordant treatment for nonmetastatic prostate cancer are more likely to die from other causes. Men with nonmetastatic prostate cancer (PCa) who receive treatment ...

Patients with nonmetastatic prostate cancer are more likely to die from other causes than from cancer when treated per guidelines. The 15-year cancer mortality risk is 5.5% for low-risk and 22% for ...

SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that its Prolaris prostate cancer ...

About 70% of physicians said they were not following the recommended guidelines for the treatment of metastatic prostate cancer, according to a study published Dec. 9 in JAMA Network Open. Metastatic ...

The National Comprehensive Cancer Network has announced that it has updated its practice guidelines for physicians to stress active surveillance rather than treatment for many men with low-risk ...

After determining there was an unmet need for guidelines for prostate cancer screening specifically for Black men, in January 2023 PCF convened a panel of experts in the social determinants of health, ...

UCSF-led study alerts transwomen and physicians to interpret standard screening guidelines with caution. Transgender women on hormone therapy tend to skew artificially low on prostate cancer screening ...

A research team from the Department of Surgery and the Department of Medicine, School of Clinical Medicine, LKS Faculty of ...

A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the best to prescribe upfront—and to which patients. Over the past 14 years, ...

Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population. A post-hoc ...